semaglutide and fda warns about safety of 'off-brand' versions of Ozempic, Wegovy therapeutic dose semaglutide FDA has

The SUSTAIN-6 trial published in 2016 showed that participants receiving weekly Ozempic (semaglutide) lost an average of 3-5 kg (8-11 lbs) after a two-year period (3)

That's not a ton of complaints, but compounding pharmacies generally don't report adverse events to the FDA

The shift favors abdominal storage, the type most closely linked to cardiovascular and metabolic risks

Mcclean PL, Parthsarathy V, Faivre E, Holscher C

Qu dice la investigacin

It has potential therapeutic benefits, including gastrointestinal protection, wound and tissue healing, muscle recovery, anti-aging effects, and even possible cardiovascular and neurological benefits